A Randomised, Double-blind, Parallel-group, Active Controlled Study Evaluating the Efficacy of Vortioxetine Versus Desvenlafaxine in Adult Patients Suffering From Major Depressive Disorder With Partial Response to SSRI Treatment
Latest Information Update: 05 Aug 2022
At a glance
- Drugs Vortioxetine (Primary) ; Desvenlafaxine
- Indications Major depressive disorder
- Focus Therapeutic Use
- Acronyms VIVRE
- Sponsors Lundbeck A/S
- 11 Apr 2022 Primary endpoint has been met, (Change in Montgomery and sberg Depression Rating Scale (MADRS) total score), according to a Lundbeck A/S Media Release.
- 11 Apr 2022 According to a Lundbeck A/S Media Release, The results of the study will be presented at The American Society for Clinical Pathology (ASCP) congress, 2022.
- 11 Apr 2022 Results presented in the Lundbeck A/S Media Release.